Biofrontera Ownership
| BFRI Stock | USD 0.88 0.03 3.53% |
Biofrontera | Build AI portfolio with Biofrontera Stock |
Biofrontera Stock Ownership Analysis
About 13.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.81. Biofrontera had not issued any dividends in recent years. The entity had 1:20 split on the 5th of July 2023. Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts. Biofrontera operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 69 people. For more info on Biofrontera please contact Erica CPA at 781 245 1325 or go to https://www.biofrontera-us.com.Biofrontera Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Biofrontera is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Biofrontera backward and forwards among themselves. Biofrontera's institutional investor refers to the entity that pools money to purchase Biofrontera's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2025-03-31 | 31.0 | Goldman Sachs Group Inc | 2025-03-31 | 0.0 | Tower Research Capital Llc | 2025-03-31 | 0.0 | Millennium Management Llc | 2025-03-31 | 0.0 | Scotia Capital Inc | 2025-03-31 | 0.0 | Advisor Group Holdings, Inc. | 2025-03-31 | 0.0 | Aigh Capital Management, Llc | 2025-03-31 | 732.2 K | Rosalind Advisors, Inc. | 2025-03-31 | 644.4 K | Geode Capital Management, Llc | 2025-03-31 | 40.1 K | Citadel Advisors Llc | 2025-03-31 | 28.2 K | Virtu Financial Llc | 2025-03-31 | 18.5 K |
Biofrontera Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biofrontera insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biofrontera's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Biofrontera insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Hermann Luebbert over a month ago Acquisition by Hermann Luebbert of 113379 shares of Biofrontera at 4.77 subject to Rule 16b-3 | ||
Borer John J Iii over three months ago Acquisition by Borer John J Iii of 22000 shares of Biofrontera subject to Rule 16b-3 | ||
Hermann Luebbert over six months ago Acquisition by Hermann Luebbert of 190840 shares of Biofrontera subject to Rule 16b-3 | ||
Hermann Luebbert over a year ago Disposition of 4771 shares by Hermann Luebbert of Biofrontera subject to Rule 16b-3 | ||
Wedge Loretta M. over a year ago Insider Trading | ||
Luebbert Hermann over a year ago Exercise or conversion by Luebbert Hermann of 95420 shares of Biofrontera subject to Rule 16b-3 |
Biofrontera Outstanding Bonds
Biofrontera issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Biofrontera uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Biofrontera bonds can be classified according to their maturity, which is the date when Biofrontera has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Currently Active Assets on Macroaxis
When determining whether Biofrontera offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biofrontera's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biofrontera Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biofrontera Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biofrontera. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more detail on how to invest in Biofrontera Stock please use our How to Invest in Biofrontera guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biofrontera. If investors know Biofrontera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biofrontera listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.81) | Revenue Per Share | Quarterly Revenue Growth 0.085 | Return On Assets | Return On Equity |
The market value of Biofrontera is measured differently than its book value, which is the value of Biofrontera that is recorded on the company's balance sheet. Investors also form their own opinion of Biofrontera's value that differs from its market value or its book value, called intrinsic value, which is Biofrontera's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biofrontera's market value can be influenced by many factors that don't directly affect Biofrontera's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biofrontera's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biofrontera is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biofrontera's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.